The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Development and Validation of a Model Consisting of Comorbidity Burden to Calculate Risk of Death Within 6 Months for Patients With Suspected Drug-Induced Liver Injury
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DILI patients with pre-existing liver disease have an increased risk of 6-month mortality at 4.5% in validation cohort and 8.5% in discovery cohort in a DILIN study.
“DILI patients with pre-existing liver disease have reported to demonstrate an increased risk of 6-month mortality at 4.5% in validation cohort and 8.5% in discovery cohort in a DILIN study [71].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [71]
A validated model incorporating MELD score, serum albumin level, and Charlson comorbidity index may be useful in predicting the 6-month risk of death in patients with DILI.
“Another validated model incorporating the Model for End-Stage Liver Disease score, the serum albumin level, and the Charlson comorbidity index as parameters may be useful in predicting the 6-month risk of death in patients with DILI [71].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [71]
DILIN group established that significant comorbidities defined by Charlson ≥ 2, Model for End-Stage Liver Disease score and serum level of albumin at presentation were independently associated with 6-month mortality in both discovery (306 patients) and validation (247 patients) cohorts.
“On the other hand, DILIN group established that significant comorbidities defined by Charlson ≥ 2, Model for End-Stage Liver Disease score and serum level of albumin at presentation were independently associated with 6-month mortality in both discovery (306 patients) and validation (247 patients) cohorts [33]”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Navarro, V. J., Barnhart, H., Bonkovsky, H. L., Davern, T., Fontana, R. J., Grant, L., Reddy, R. K., Seeff, L. B., Serrano, J., Sherker, A. H., et al. (2014) · Hepatology · doi:10.1002/hep.27317 · Cited by 418
Self-citation
Flagged first, then by citations
Research works printed but not linked: 19
- Chalasani, 2014, ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury, Am J Gastroenterol, 109, 950, 10.1038/ajg.2014.131 · DOI · Paper page
- Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
- Hayashi, 2017, Death and liver transplantation within 2 years of onset of drug-induced liver injury, Hepatology, 66, 1275, 10.1002/hep.29283 · DOI · Paper page
- Natarajan, 2017, Role of non-hepatic medical comorbidity and functional limitations in predicting mortality in patients with HCV, Dig Dis Sci, 62, 76, 10.1007/s10620-016-4303-2 · DOI
- Ladha, 2015, The Deyo-Charlson and Elixhauser-van Walraven Comorbidity Indices as predictors of mortality in critically ill patients, BMJ Open, 5, 10.1136/bmjopen-2015-008990 · DOI
- Xu, 2017, Comparison of risk adjustment methods in patients with liver disease using electronic medical record data, BMC Gastroenterol, 17, 5, 10.1186/s12876-016-0559-4 · DOI
- Fontana, 2009, Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct, Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
- Dakhoul, 2018, Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers, Clin Gastroenterol Hepatol, 16, 722, 10.1016/j.cgh.2017.12.036 · DOI · Paper page
- Chalasani, 2017, Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians, Am J Gastroenterol, 112, 1382, 10.1038/ajg.2017.215 · DOI · Paper page
- Fontana, 2015, Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury, Am J Gastroenterol, 110, 1450, 10.1038/ajg.2015.283 · DOI
- Fontana, 2014, Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset, Gastroenterology, 147, 96, 10.1053/j.gastro.2014.03.045 · DOI
- Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8 · DOI · Paper page
- Rattanasompattikul, 2012, Charlson Comorbidity score is a strong predictor of mortality in hemodialysis patients, Int Urol Nephrol, 44, 1813, 10.1007/s11255-011-0085-9 · DOI
- Formiga, 2018, High comorbidity, measured by the Charlson Comorbidity Index, associates with higher 1-year mortality risks in elderly patients experiencing a first acute heart failure hospitalization, Aging Clin Exp Res, 30, 927, 10.1007/s40520-017-0853-1 · DOI
- Fraccaro, 2016, Predicting mortality from change-over-time in the Charlson Comorbidity Index: a retrospective cohort study in a data-intensive UK health system, Medicine (Baltimore), 95, 10.1097/MD.0000000000004973 · DOI
- Chalasani, 2008, Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States, Gastroenterology, 135, 1924, 10.1053/j.gastro.2008.09.011 · DOI
- Gottlieb, 2019, How to define acute liver failure patients with pre-existing liver disease without signs of cirrhosis, Dig Dis, 37, 147, 10.1159/000492869 · DOI
- Canbay, 2005, Overweight patients are more susceptible for acute liver failure, Hepatogastroenterology, 52, 1516
- Canbay, 2009, Acute liver failure in a metropolitan area in Germany: a retrospective study (2002–2008), Z Gastroenterol, 47, 807
Cited by
Sorted by citations
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
Self-citationACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & on behalf of the Practice Parameters Committee of the American College of Gastroenterology (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001259 · Cited by 430
Self-citationAASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
The contemporary epidemiology, causes, and management of drug-induced liver injury
Swanson, L., & Fontana, R. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001011
DILI Differences and Similarities between the US and Europe
Toro-Ortiz, J. P., Andrade, R. J., & Pinazo-Bandera, J. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00733-x
Metadata
- Authors
- Ghabril, M., Gu, J., Yoder, L., Corbito, L., Ringel, A., Beyer, C. D., Vuppalanchi, R., Barnhart, H., Hayashi, P. H., & Chalasani, N.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 157
- Issue
- 5
- Pages
- 1245-1252.e3
- ISSN
- 0016-5085
- PMC
- PMC6815697
- Cited by
- 52
- References
- 1
- Language
- en
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases
- AbbVie
- Eli Lilly and Company
- Duke University (DK065201, DK065211)
- Genentech
- Indiana University (U01)
- Siemens Foundation
- University of North Carolina
- Allergan Foundation
- Gilead Sciences
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
